Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 74 | 2023 | 1248 | 7.820 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 37 | 2023 | 1624 | 3.490 |
Why?
|
Radiotherapy Dosage | 45 | 2023 | 2879 | 2.000 |
Why?
|
Genital Neoplasms, Female | 8 | 2023 | 523 | 1.520 |
Why?
|
Catheters | 11 | 2023 | 425 | 1.340 |
Why?
|
Radiometry | 16 | 2020 | 800 | 1.240 |
Why?
|
Prostatic Neoplasms | 40 | 2021 | 11124 | 1.140 |
Why?
|
Rectum | 14 | 2017 | 904 | 0.980 |
Why?
|
Iodine Radioisotopes | 10 | 2012 | 1032 | 0.940 |
Why?
|
Radiation Dosage | 8 | 2017 | 1928 | 0.750 |
Why?
|
Organs at Risk | 4 | 2017 | 346 | 0.610 |
Why?
|
Gold | 5 | 2014 | 484 | 0.600 |
Why?
|
Film Dosimetry | 3 | 2020 | 29 | 0.590 |
Why?
|
Prostate | 12 | 2021 | 1774 | 0.540 |
Why?
|
Radiotherapy, Conformal | 7 | 2011 | 548 | 0.540 |
Why?
|
Magnetic Resonance Imaging | 32 | 2023 | 35421 | 0.530 |
Why?
|
Needles | 2 | 2022 | 449 | 0.520 |
Why?
|
Software Validation | 1 | 2014 | 59 | 0.500 |
Why?
|
Metal Nanoparticles | 3 | 2014 | 405 | 0.490 |
Why?
|
Uterine Cervical Neoplasms | 9 | 2021 | 2020 | 0.480 |
Why?
|
Cone-Beam Computed Tomography | 3 | 2015 | 450 | 0.480 |
Why?
|
Electromagnetic Phenomena | 1 | 2014 | 161 | 0.460 |
Why?
|
Urinary Bladder | 8 | 2017 | 1172 | 0.440 |
Why?
|
Phantoms, Imaging | 10 | 2022 | 2480 | 0.430 |
Why?
|
Uncertainty | 2 | 2014 | 734 | 0.390 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2010 | 358 | 0.380 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2017 | 876 | 0.370 |
Why?
|
Drug Implants | 3 | 2016 | 244 | 0.370 |
Why?
|
Artifacts | 7 | 2015 | 1904 | 0.370 |
Why?
|
Radiation Injuries | 6 | 2010 | 1180 | 0.350 |
Why?
|
Colon, Sigmoid | 5 | 2017 | 120 | 0.340 |
Why?
|
Quality Control | 4 | 2019 | 841 | 0.340 |
Why?
|
Catheterization | 2 | 2012 | 1470 | 0.330 |
Why?
|
Imaging, Three-Dimensional | 7 | 2015 | 4042 | 0.320 |
Why?
|
Monte Carlo Method | 4 | 2009 | 1254 | 0.320 |
Why?
|
Strontium Radioisotopes | 2 | 2004 | 18 | 0.300 |
Why?
|
Radiation Protection | 3 | 2010 | 419 | 0.300 |
Why?
|
Models, Theoretical | 4 | 2017 | 3589 | 0.280 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2014 | 8949 | 0.280 |
Why?
|
Tomography, X-Ray Computed | 16 | 2021 | 20129 | 0.280 |
Why?
|
Radiotherapy, Computer-Assisted | 4 | 2014 | 94 | 0.270 |
Why?
|
Algorithms | 11 | 2021 | 13881 | 0.270 |
Why?
|
Quality Assurance, Health Care | 3 | 2017 | 2212 | 0.260 |
Why?
|
Magnetic Resonance Imaging, Interventional | 3 | 2017 | 182 | 0.240 |
Why?
|
Iridium Radioisotopes | 1 | 2004 | 26 | 0.240 |
Why?
|
Models, Biological | 5 | 2014 | 9583 | 0.230 |
Why?
|
Prostheses and Implants | 3 | 2013 | 1387 | 0.230 |
Why?
|
Pattern Recognition, Automated | 3 | 2014 | 1005 | 0.210 |
Why?
|
Radiotherapy | 3 | 2011 | 1533 | 0.210 |
Why?
|
Feasibility Studies | 7 | 2021 | 5078 | 0.210 |
Why?
|
Fiducial Markers | 2 | 2014 | 136 | 0.200 |
Why?
|
Ultrasonography, Interventional | 2 | 2014 | 1486 | 0.190 |
Why?
|
Catheters, Indwelling | 2 | 2014 | 426 | 0.190 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 806 | 0.190 |
Why?
|
Uterine Neoplasms | 3 | 2017 | 1513 | 0.190 |
Why?
|
Graft Occlusion, Vascular | 1 | 2004 | 549 | 0.180 |
Why?
|
Radiography, Interventional | 1 | 2008 | 1095 | 0.180 |
Why?
|
Coronary Restenosis | 1 | 2003 | 424 | 0.180 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2012 | 3327 | 0.180 |
Why?
|
Humans | 91 | 2023 | 744343 | 0.180 |
Why?
|
Breast | 2 | 2008 | 1969 | 0.180 |
Why?
|
Electrical Equipment and Supplies | 1 | 2019 | 27 | 0.180 |
Why?
|
Prostate-Specific Antigen | 7 | 2019 | 2494 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2019 | 9239 | 0.170 |
Why?
|
Vaginal Neoplasms | 2 | 2012 | 106 | 0.160 |
Why?
|
Reproducibility of Results | 12 | 2015 | 19905 | 0.160 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1157 | 0.160 |
Why?
|
Calibration | 4 | 2019 | 816 | 0.150 |
Why?
|
Sensitivity and Specificity | 9 | 2014 | 14722 | 0.150 |
Why?
|
Adenocarcinoma | 6 | 2016 | 6364 | 0.140 |
Why?
|
Nanoparticles | 3 | 2016 | 1905 | 0.140 |
Why?
|
Immobilization | 2 | 2012 | 236 | 0.140 |
Why?
|
Research Report | 1 | 2019 | 355 | 0.140 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2016 | 68 | 0.140 |
Why?
|
Eye Neoplasms | 1 | 1998 | 313 | 0.140 |
Why?
|
Biopsy, Needle | 2 | 2001 | 1641 | 0.140 |
Why?
|
Retinoblastoma | 1 | 1998 | 318 | 0.130 |
Why?
|
Equipment Design | 4 | 2017 | 3582 | 0.130 |
Why?
|
Numerical Analysis, Computer-Assisted | 2 | 2006 | 125 | 0.130 |
Why?
|
Male | 44 | 2021 | 350118 | 0.130 |
Why?
|
Phthalazines | 1 | 2017 | 363 | 0.120 |
Why?
|
Nanocapsules | 1 | 2015 | 91 | 0.120 |
Why?
|
Silicon Dioxide | 1 | 2015 | 213 | 0.120 |
Why?
|
Electrons | 1 | 2014 | 268 | 0.110 |
Why?
|
Fluorescence | 1 | 2016 | 751 | 0.110 |
Why?
|
Technology, Radiologic | 2 | 2007 | 163 | 0.110 |
Why?
|
Chitosan | 2 | 2010 | 141 | 0.110 |
Why?
|
Lung Neoplasms | 3 | 2021 | 13102 | 0.100 |
Why?
|
Urinary Retention | 2 | 2005 | 111 | 0.100 |
Why?
|
Drug Delivery Systems | 2 | 2016 | 2219 | 0.100 |
Why?
|
Surface Properties | 2 | 2012 | 1184 | 0.100 |
Why?
|
Retrospective Studies | 16 | 2021 | 77449 | 0.100 |
Why?
|
Air | 1 | 2012 | 182 | 0.100 |
Why?
|
Intraoperative Period | 1 | 2012 | 520 | 0.100 |
Why?
|
Software | 4 | 2021 | 4443 | 0.100 |
Why?
|
Taxoids | 1 | 2015 | 666 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2948 | 0.100 |
Why?
|
Gamma Rays | 1 | 2012 | 320 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1142 | 0.100 |
Why?
|
Piperazines | 2 | 2017 | 2488 | 0.100 |
Why?
|
Computer Simulation | 7 | 2014 | 6196 | 0.100 |
Why?
|
Skin Diseases | 1 | 2020 | 1065 | 0.100 |
Why?
|
Female | 28 | 2023 | 380194 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2012 | 1770 | 0.100 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2016 | 721 | 0.090 |
Why?
|
Risk Assessment | 4 | 2019 | 23338 | 0.090 |
Why?
|
Metals | 1 | 2014 | 719 | 0.090 |
Why?
|
Prospective Studies | 11 | 2021 | 53288 | 0.090 |
Why?
|
Neoplasms, Experimental | 1 | 2015 | 1276 | 0.090 |
Why?
|
Water | 1 | 2015 | 1395 | 0.090 |
Why?
|
Carcinoid Tumor | 2 | 2009 | 235 | 0.080 |
Why?
|
Polyglycolic Acid | 1 | 2010 | 407 | 0.080 |
Why?
|
Breast Neoplasms | 4 | 2010 | 20822 | 0.080 |
Why?
|
Subtraction Technique | 1 | 2012 | 525 | 0.080 |
Why?
|
Dental Restoration, Permanent | 1 | 2009 | 127 | 0.080 |
Why?
|
Cisplatin | 1 | 2014 | 1662 | 0.080 |
Why?
|
Light | 1 | 2014 | 1374 | 0.080 |
Why?
|
X-Ray Film | 1 | 2008 | 33 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2007 | 1130 | 0.080 |
Why?
|
Drug Approval | 1 | 2014 | 742 | 0.080 |
Why?
|
Treatment Outcome | 13 | 2018 | 63114 | 0.080 |
Why?
|
Vagina | 3 | 2010 | 825 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2016 | 4034 | 0.080 |
Why?
|
Societies, Medical | 1 | 2019 | 3743 | 0.080 |
Why?
|
Endometrial Neoplasms | 2 | 2008 | 1353 | 0.080 |
Why?
|
Transistors, Electronic | 1 | 2007 | 19 | 0.080 |
Why?
|
Organ Size | 1 | 2012 | 2252 | 0.080 |
Why?
|
Urethra | 3 | 2008 | 408 | 0.070 |
Why?
|
Apoptosis | 1 | 2023 | 9727 | 0.070 |
Why?
|
Thoracic Neoplasms | 1 | 2009 | 268 | 0.070 |
Why?
|
Robotics | 1 | 2014 | 899 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2014 | 1584 | 0.070 |
Why?
|
Skin Physiological Phenomena | 1 | 2007 | 180 | 0.070 |
Why?
|
Rectal Diseases | 1 | 2007 | 143 | 0.070 |
Why?
|
HeLa Cells | 1 | 2012 | 3128 | 0.070 |
Why?
|
Delayed-Action Preparations | 1 | 2009 | 968 | 0.070 |
Why?
|
Drug Carriers | 1 | 2010 | 693 | 0.070 |
Why?
|
Motion | 2 | 2006 | 798 | 0.070 |
Why?
|
Aged | 24 | 2019 | 163280 | 0.070 |
Why?
|
Peer Review | 1 | 2008 | 209 | 0.070 |
Why?
|
Radiography | 3 | 2006 | 7023 | 0.070 |
Why?
|
Survival Rate | 3 | 2019 | 12788 | 0.060 |
Why?
|
Lactic Acid | 1 | 2010 | 1133 | 0.060 |
Why?
|
Movement | 1 | 2012 | 1471 | 0.060 |
Why?
|
Computer Systems | 3 | 2003 | 483 | 0.060 |
Why?
|
Body Burden | 1 | 2005 | 158 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2012 | 2309 | 0.060 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2006 | 234 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5221 | 0.060 |
Why?
|
Salvage Therapy | 2 | 2009 | 1275 | 0.060 |
Why?
|
Finite Element Analysis | 1 | 2006 | 431 | 0.060 |
Why?
|
Carcinoma | 2 | 2007 | 2375 | 0.060 |
Why?
|
Beta Particles | 1 | 2003 | 50 | 0.060 |
Why?
|
Mediastinal Neoplasms | 1 | 2006 | 423 | 0.060 |
Why?
|
Middle Aged | 24 | 2019 | 213383 | 0.060 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 1184 | 0.060 |
Why?
|
Relative Biological Effectiveness | 1 | 2005 | 323 | 0.060 |
Why?
|
Ultrasonography | 2 | 2014 | 5985 | 0.050 |
Why?
|
Medical Errors | 1 | 2011 | 1297 | 0.050 |
Why?
|
Yttrium Radioisotopes | 1 | 2003 | 93 | 0.050 |
Why?
|
bcl-2-Associated X Protein | 1 | 2023 | 295 | 0.050 |
Why?
|
Rotation | 2 | 2008 | 523 | 0.050 |
Why?
|
Self Medication | 1 | 2002 | 117 | 0.050 |
Why?
|
Watchful Waiting | 2 | 2018 | 492 | 0.050 |
Why?
|
Niacin | 1 | 2002 | 116 | 0.050 |
Why?
|
Quality Improvement | 1 | 2017 | 3749 | 0.050 |
Why?
|
User-Computer Interface | 2 | 2017 | 1431 | 0.050 |
Why?
|
Biophysical Phenomena | 2 | 2001 | 327 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 2018 | 39050 | 0.050 |
Why?
|
Biophysics | 2 | 2001 | 383 | 0.050 |
Why?
|
Neoplasm Staging | 5 | 2018 | 11031 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2017 | 57776 | 0.050 |
Why?
|
Massachusetts | 1 | 2013 | 8663 | 0.040 |
Why?
|
Organ Specificity | 1 | 2005 | 2008 | 0.040 |
Why?
|
Prostatic Hyperplasia | 2 | 2000 | 523 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6538 | 0.040 |
Why?
|
Urination Disorders | 1 | 2000 | 241 | 0.040 |
Why?
|
Neoplasms | 4 | 2014 | 21683 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 764 | 0.040 |
Why?
|
Perineum | 1 | 2000 | 211 | 0.040 |
Why?
|
Cell Death | 1 | 2023 | 1706 | 0.040 |
Why?
|
Drug Interactions | 1 | 2002 | 1460 | 0.040 |
Why?
|
Head and Neck Neoplasms | 2 | 2009 | 2734 | 0.040 |
Why?
|
Coronary Stenosis | 1 | 2004 | 834 | 0.040 |
Why?
|
Kinetics | 2 | 2019 | 6473 | 0.040 |
Why?
|
Automation | 1 | 2020 | 584 | 0.040 |
Why?
|
Risk Factors | 6 | 2018 | 72290 | 0.040 |
Why?
|
Scattering, Radiation | 1 | 1998 | 498 | 0.030 |
Why?
|
Lens, Crystalline | 1 | 1998 | 388 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15226 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12354 | 0.030 |
Why?
|
Workflow | 1 | 2019 | 847 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40075 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10943 | 0.030 |
Why?
|
Prostatectomy | 1 | 2003 | 1890 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13695 | 0.030 |
Why?
|
Image Enhancement | 3 | 2014 | 2921 | 0.030 |
Why?
|
Vascular Diseases | 1 | 2003 | 1161 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2017 | 486 | 0.030 |
Why?
|
Mammaplasty | 1 | 2005 | 1204 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7279 | 0.030 |
Why?
|
Coronary Artery Bypass | 1 | 2004 | 2289 | 0.030 |
Why?
|
Diffusion | 1 | 2016 | 833 | 0.030 |
Why?
|
Adult | 8 | 2017 | 214055 | 0.030 |
Why?
|
Animals | 7 | 2023 | 168757 | 0.030 |
Why?
|
Mammography | 1 | 2005 | 2476 | 0.030 |
Why?
|
Risk Management | 1 | 2017 | 571 | 0.030 |
Why?
|
Artificial Intelligence | 1 | 2006 | 2214 | 0.030 |
Why?
|
Electromagnetic Fields | 1 | 2014 | 298 | 0.030 |
Why?
|
Chickens | 1 | 2014 | 865 | 0.030 |
Why?
|
Computer Graphics | 1 | 2014 | 361 | 0.030 |
Why?
|
Nanostructures | 1 | 2017 | 551 | 0.030 |
Why?
|
Particle Size | 1 | 2016 | 1642 | 0.030 |
Why?
|
Swine | 1 | 2021 | 5917 | 0.020 |
Why?
|
Boston | 2 | 2017 | 9313 | 0.020 |
Why?
|
Prognosis | 3 | 2019 | 29063 | 0.020 |
Why?
|
Mice | 4 | 2023 | 81183 | 0.020 |
Why?
|
Nanomedicine | 1 | 2014 | 304 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2021 | 3760 | 0.020 |
Why?
|
Equipment Failure | 1 | 2013 | 578 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6895 | 0.020 |
Why?
|
Radiation Oncology | 1 | 2017 | 555 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1915 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2014 | 2327 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2017 | 1149 | 0.020 |
Why?
|
Fluoresceins | 1 | 2010 | 235 | 0.020 |
Why?
|
Drug Stability | 1 | 2010 | 291 | 0.020 |
Why?
|
Polymethyl Methacrylate | 1 | 2010 | 145 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 16689 | 0.020 |
Why?
|
Mice, Nude | 1 | 2016 | 3689 | 0.020 |
Why?
|
Intraoperative Care | 2 | 2003 | 767 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5952 | 0.020 |
Why?
|
Drug Compounding | 1 | 2010 | 242 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3557 | 0.020 |
Why?
|
Dental Amalgam | 1 | 2009 | 67 | 0.020 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 407 | 0.020 |
Why?
|
Dental Materials | 1 | 2009 | 108 | 0.020 |
Why?
|
Mastectomy | 2 | 2008 | 1793 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2011 | 402 | 0.020 |
Why?
|
Nanotechnology | 1 | 2014 | 710 | 0.020 |
Why?
|
Biopsy | 1 | 2000 | 6756 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4851 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2593 | 0.020 |
Why?
|
Mediastinum | 1 | 2009 | 267 | 0.020 |
Why?
|
Quality of Life | 1 | 2009 | 12804 | 0.020 |
Why?
|
Male Urogenital Diseases | 1 | 2007 | 48 | 0.020 |
Why?
|
Retina | 1 | 1998 | 2616 | 0.020 |
Why?
|
X-Rays | 1 | 1987 | 301 | 0.020 |
Why?
|
Fecal Incontinence | 1 | 2009 | 239 | 0.020 |
Why?
|
Treatment Failure | 1 | 2012 | 2618 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2010 | 885 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 2971 | 0.020 |
Why?
|
Online Systems | 1 | 2006 | 184 | 0.020 |
Why?
|
Erectile Dysfunction | 1 | 2009 | 461 | 0.020 |
Why?
|
Postoperative Care | 1 | 2012 | 1486 | 0.020 |
Why?
|
Leiomyosarcoma | 1 | 2009 | 477 | 0.020 |
Why?
|
Urinary Incontinence | 1 | 2009 | 496 | 0.020 |
Why?
|
Tongue Neoplasms | 1 | 2006 | 180 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 973 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2007 | 868 | 0.020 |
Why?
|
Doxorubicin | 1 | 2010 | 2234 | 0.010 |
Why?
|
Pelvis | 1 | 2008 | 730 | 0.010 |
Why?
|
Life Tables | 1 | 2003 | 370 | 0.010 |
Why?
|
Preoperative Care | 2 | 2002 | 2250 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 461 | 0.010 |
Why?
|
Precipitating Factors | 1 | 2002 | 52 | 0.010 |
Why?
|
Proctitis | 1 | 2002 | 40 | 0.010 |
Why?
|
Ejaculation | 1 | 2002 | 58 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1708 | 0.010 |
Why?
|
Prothrombin Time | 1 | 2002 | 119 | 0.010 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 274 | 0.010 |
Why?
|
Feedback | 1 | 2006 | 795 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2716 | 0.010 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 1101 | 0.010 |
Why?
|
Child, Preschool | 1 | 2023 | 41006 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23403 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9687 | 0.010 |
Why?
|
Peritoneum | 1 | 2000 | 228 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2014 | 4371 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 1170 | 0.010 |
Why?
|
Odds Ratio | 1 | 2011 | 9849 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 3479 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18029 | 0.010 |
Why?
|
Sarcoma | 1 | 2009 | 1897 | 0.010 |
Why?
|
Antibiotic Prophylaxis | 1 | 2002 | 639 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2008 | 3474 | 0.010 |
Why?
|
Young Adult | 2 | 2016 | 56430 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2002 | 921 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13408 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11524 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2003 | 3616 | 0.010 |
Why?
|
Child | 1 | 2023 | 77709 | 0.010 |
Why?
|
United States | 2 | 2014 | 69872 | 0.010 |
Why?
|
Heart | 1 | 2008 | 4467 | 0.010 |
Why?
|
Adolescent | 2 | 2016 | 85781 | 0.010 |
Why?
|
Acute Disease | 1 | 2005 | 7149 | 0.010 |
Why?
|
Pilot Projects | 1 | 2006 | 8324 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2003 | 2728 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 7913 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5102 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6365 | 0.010 |
Why?
|
Regression Analysis | 1 | 2000 | 6459 | 0.010 |
Why?
|
Lung | 1 | 2008 | 9856 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2002 | 12959 | 0.000 |
Why?
|
Patient Selection | 1 | 1998 | 4215 | 0.000 |
Why?
|